<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607527</url>
  </required_header>
  <id_info>
    <org_study_id>CP-002, CP-003</org_study_id>
    <nct_id>NCT02607527</nct_id>
  </id_info>
  <brief_title>Annular Reshaping of the Mitral Valve for MR Using the Millipede IRIS System</brief_title>
  <official_title>Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millipede Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meditrial Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Millipede Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi center evaluation of the Millipede IRIS for treatment of clinically significant mitral
      regurgitation in subjects determined appropriate for mitral valve surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi center evaluation of the Millipede IRIS for treatment of clinically significant mitral
      regurgitation in subjects determined appropriate for mitral valve surgery.

      This trial is designed in accordance with the 2014 ACC/AHA guidelines for valvular heart
      disease, and the consensus statement of MVARC 2015.

      Subjects will undergo transatrial implantation of the Millipede IRIS implant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Safety defined as incidence of adverse events</measure>
    <time_frame>Procedure through 30 days post procedure</time_frame>
    <description>30 days defined as ability to implant, anchor and actuate without incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by reduction in mitral regurgitation without significant mitral stenosis as measured by echo</measure>
    <time_frame>Procedural through 48 hrs post procedure</time_frame>
    <description>Reduction in mitral regurgitation to optimal or acceptable levels without significant mitral stenosis post procedure (defined as discharge or 48 hrs whichever comes first) and EROA &lt;1.5 cm2 with transmitral gradient &lt;5mm Hg as compared to screening echo</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Device Implantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mitral Valve Iris Ring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral Valve IRIS Ring</intervention_name>
    <description>implantation of mitral implant surgically or mini thoracotomy</description>
    <arm_group_label>Device Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of symptomatic severe MR (effective regurgitant orifice (ERO) ≥0.2 cm2 for
             Secondary MR, ERO ≥0.4 cm2 for Primary MR)

          -  The New York Heart Association Functional Class II, III or ambulatory IV.

          -  Left Ventricular Ejection Fraction (LVEF) is ≥20% and ≤50%

          -  Creatine Kinase-MB (CK-MB) obtained within prior 14 days &lt; local laboratory -Upper
             Limit of Normal (ULN).

          -  Left Ventricular End Systolic Dimension (LVESD) is ≤ 65 mm assessed by TTE obtained
             within 90 days Exclusion Criteria: -Untreated clinically significant coronary artery
             disease requiring revascularization.

        Presence of any of the following:

          -  Estimated pulmonary artery systolic pressure (PASP) &gt; 70 mmHg assessed by site based
             on echocardiography or right heart catheterization

          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or
             any other structural heart disease causing heart failure other than dilated
             cardiomyopathy of either ischemic or non-ischemic etiology

          -  Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)

          -  Hemodynamic instability requiring inotropic support or mechanical heart assistance.

          -  Hemodynamic instability defined as systolic pressure &lt; 90 mmHg with or without
             afterload reduction, cardiogenic shock or the need for inotropic support or
             intra-aortic balloon pump or other hemodynamic support device.

          -  Physical evidence of right-sided congestive heart failure with echocardiographic
             evidence of moderate or severe right ventricular dysfunction.

          -  Coronary artery bypass grafting (CABG) within 30 days prior to subject's consent.

          -  Percutaneous coronary intervention within 30 days prior to subject's consent.

          -  Tricuspid valve disease requiring surgery.

          -  Aortic valve disease requiring surgery or TAVI.

          -  Carotid surgery within 30 days prior to subject registration.

          -  Implant of any Cardiac Resynchronization Therapy (CRT) or Cardiac -Resynchronization
             Therapy with cardioverter-defibrillator (CRT-D) within the last 30 days prior to
             subject registration.

          -  Need for emergent or urgent surgery for any reason or any planned cardiac surgery
             within the next 12 months.

          -  Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve,
             or any prior transcatheter mitral valve procedure.

          -  Status 1 heart transplant or prior orthotopic heart transplantation.

          -  Chronic Kidney Disease.

          -  Chronic Steroid Therapy.

          -  Cerebrovascular accident within 30 days prior to subject's consent.

          -  Severe symptomatic carotid stenosis (&gt; 70% by ultrasound).Life expectancy &lt; 12 months
             due to non-cardiac conditions.

          -  Active infections requiring current antibiotic therapy.

          -  Pregnant or planning pregnancy within next 12 months.

          -  Currently participating in an investigational drug or another device study.

          -  Severe organic lesions with mitral chords retraction, severely fibrotic and immobile
             leaflets, severely deformed subvalvular apparatus.

          -  endocarditis or active endocarditis in the last 3 months.

          -  Heavily calcified annulus or leaflets, mitral valve stenosis.

          -  Congenital malformation with limited valvular tissue

          -  Patient requires mitral valve replacement

          -  Previously implanted prosthetic mitral valve or annuloplasty ring/band.

          -  Evidence of LV or LA thrombus, vegetation or mass

          -  Left Ventricular Ejection Fraction &lt;20%

          -  Left Ventricular End Diastolic Diameter &gt;65 mm

          -  Severe tricuspid regurgitation or severe RV dysfunction

          -  Condition that prevents transatrial access or transfemoral access

          -  Anatomical ineligibility to the investigational device

          -  Known hypersensitivity or contraindication to procedural or post procedural medication
             (e.g., contrast solution, anticoagulation therapy) or hypersensitivity to nickel or
             titanium.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Abizaid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dante Pazzanese de Cardiologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Sheahan</last_name>
    <phone>7074838184</phone>
    <email>brian.sheahan@millipedemedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Minarsch</last_name>
    <phone>9492805700</phone>
    <email>laura22@mmc-medical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sanatorio Italiano</name>
      <address>
        <city>Asunción</city>
        <zip>1023</zip>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Ebner, MD</last_name>
      <phone>+59521202767</phone>
      <email>adrianeb@ebner.com.py</email>
    </contact>
    <contact_backup>
      <last_name>Santiago Gallo, MD</last_name>
      <phone>+595981460594</phone>
      <email>santigallo56@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Adrian Ebner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Paraguay</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

